News coverage about Omnicell (NASDAQ:OMCL) has trended somewhat positive on Friday, AlphaOne Sentiment reports. AlphaOne, a service of Accern, identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omnicell earned a daily sentiment score of 0.02 on AlphaOne’s scale. AlphaOne also assigned media coverage about the company an impact score of 35 out of 100, indicating that recent press coverage is unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Alpha One’s scoring:
- Advanced Pharmacy Informatics Capabilities Enhance Performance Center Offering (pressreleasepoint.com)
- Omnicell : Sources Sought Notice – 65– Single Cell Omnicell Anesthesia Storage Cabinets (4-traders.com)
- Omnicell (OMCL) Announces Acquisition of InPharmics (streetinsider.com)
- Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $151.88 Million (americanbankingnews.com)
- Omnicell Acquires InPharmics (finance.yahoo.com)
Several research analysts have recently commented on the stock. TheStreet upgraded shares of Omnicell from a “c” rating to a “b-” rating in a research note on Wednesday, February 15th. Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 24th. Piper Jaffray Companies lowered shares of Omnicell from an “overweight” rating to a “neutral” rating in a research note on Friday. Dougherty & Co began coverage on shares of Omnicell in a research note on Thursday, January 19th. They issued a “buy” rating and a $44.00 target price on the stock. Finally, Cantor Fitzgerald raised their target price on shares of Omnicell from $38.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, March 6th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $44.71.
Omnicell (NASDAQ:OMCL) traded down 2.02% during trading on Friday, hitting $39.95. 274,113 shares of the stock were exchanged. Omnicell has a 52 week low of $28.76 and a 52 week high of $41.15. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of 2350.00 and a beta of 0.76. The firm has a 50-day moving average of $39.49 and a 200-day moving average of $36.06.
Omnicell (NASDAQ:OMCL) last released its earnings results on Wednesday, February 15th. The company reported $0.37 EPS for the quarter, missing the Zacks’ consensus estimate of $0.41 by $0.04. The business had revenue of $171.97 million for the quarter, compared to the consensus estimate of $179.28 million. Omnicell had a return on equity of 10.74% and a net margin of 1.24%. Equities research analysts anticipate that Omnicell will post $1.36 earnings per share for the current fiscal year.
In related news, Director Sara J. White sold 3,443 shares of Omnicell stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $38.06, for a total value of $131,040.58. Following the completion of the sale, the director now owns 43,214 shares of the company’s stock, valued at approximately $1,644,724.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Gary S. Petersmeyer sold 2,658 shares of Omnicell stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $37.45, for a total value of $99,542.10. Following the completion of the sale, the director now directly owns 20,085 shares of the company’s stock, valued at approximately $752,183.25. The disclosure for this sale can be found here. Insiders own 3.75% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Omnicell (OMCL) Getting Somewhat Favorable Press Coverage, Study Finds” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/04/21/omnicell-omcl-earns-coverage-optimism-rating-of-0-02-updated.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.